EGFR and gastric cancer: Therefore, our findings uncover the contexts in which a recognized cytoskeletal protein MICAL‐L2 functions to keep EGFR content and selective inhibition of MICAL‐L2 may represent a new potential target for gastric cancer metastasis therapy.